Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review
Abstract
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Selection
2.2. Data Extraction
2.3. Data Analysis
3. Results
3.1. Study Selection
3.2. Study Characteristics
Author, Year | Study Design | Study Period | Patients (n) | Stage at Diagnosis | Previous Treatment n (%) | Chemotherapy n (%) | Response n (%) | PFS (mo) Median (Range) | OS (mo) Median (Range) | FU (mo) Median (Range) | Disease Status n (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Tresukosol, 1995 [34] | retrospective case report | 1992–1994 | 1 | IC 1 | S ×1, CT ×1 | paclitaxel 1(100) | PR 1 (100) | 12 | 24+ 1 | 24 1 | AWD 1 (100) 1 |
Shavit, 2012 [35] | retrospective case report | 2006–2007 | 1 | IA | S ×2, CT ×2 | docetaxel 1 (100) | SD 1 (100) | 24 | NA | 24 | NA |
Uygun, 2003 [36] | retrospective cohort | 1979–1999 | 4 | IIIB-IV | S 4 (100) CT 4 (100) | CC 3 (75) CAP 1 (25) | CR 2 (50) PR 2 (50) | 38 (21–73) 1 | 40.5 (33–73) 1 | 40.5 (33–73) 1 | NED 2 (50) DOD 1 (25) DOC 1 (25) |
Pectasides, 2008 [37] | retrospective cohort | 1983–2007 | 5 | IA-IV | S 5 (100) CT 5 (100) | CP 2 (40) CVB 1 (10) 5FU 2 (40) | CR 2 (40) PR 1 (20) PD 2 (40) | 7 (0–31) 1 | 28 (4–31) 1 | NA | AWD 4 (80) DOD 1 (20) |
van Meurs, 2014 [16] | retrospective cohort | 1968–2011 | 9 | I-IIIC | S 9 (100) RT 1 (11) AHT 1 (11) | BEP 9 (100) | CR 1 (11) PR 1 (11) SD 7 (78) | 12 (2–50) | 50 (4–165) | NA | NED 2 (22) AWD 3 (33) DOD 3 (33) DOC 1 (11) |
Wilson, 2015 [30] | retrospective cohort | 1955–2012 | 17 2 | IA-IC | S 17 (100) CT ns, RT ns | CT 17 (100) | CR 1 (3) PR 8 (27) SD 4 (13) PD 15 (50) ×1 3 | 8.6 | NA | NA | NA |
Brown, 2004 [11] | retrospective cohort | 1985–2002 | 21aGCT /30SCST | IA-IIIC | S 30 (100) CT 22 (73) RT 2 (7) | NPT 17 (57) PT 13 (43) | CR 3 (10) PR 7 (23) SD 7 (23) PD 12 (40) 4 | 16.8 (0–68) | NA | 100.7 (8.1–361.3) | NED 3 (10) AWD 20 (67) DOD 5 (17) DOC 2 (6) |
Pautier, 2008 [13] | prospective cohort | 1990–2002 | 14aGCT /20GCT | I-IV | S 20 (100) CT 1 (5) | BEP 20 (100) | CR 9 (45) PR 9 (45) SD 1 (5) PD 1 (5) | 24 (4–84) | 46 | 45 (3–112) | NED 9 (45) AWD 3 (15) DOD 8 (40) |
Burton, 2016 [31] | prospective cohort | 2000–2013 | 31 SCST | NA | S 31 (100) CT 24 (77) RT 3 (10) AHT 3 (10) IT 1 (3) | paclitaxel 31 (100) | CR 1(3) PR 8 (26) SD 15 (48) PD 6 (19) 5 | 10 | 73.6 | 67 | AWD 15 (48) DOD 16 (52) |
Ray-Coquard, 2020 [32] | prospective RCT | 2013–2020 | 27aGCT /32 SCST | I-IV | S 32 (100) CT 32 (100) RT 4 (13) AHT 8 (25) | paclitaxel 32 (100) | CR 0 (0) PR 8 (25) SD 17 (53) PD 7 (22) | 14.7 (95% CI 11.5–18.3) | NA | 38.9 (IQR 36.4–43.8) | AWD 26 (81) DOD 6 (19) |
Author, Year | Study Design | Study Period | Patients (n) | Stage at Diagnosis | Previous Treatment n (%) | Anti-Hormonal Therapy n (%) | Response n (%) | PFS (mo) or Median (Range) | OS (mo) Median (Range) | FU (mo) Median (Range) | Disease Status n (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Fishman, 1996 [38] | retrospective cohort | 1991–1996 | 4 | NA | CT 4 (100) AHT 1 (25) | leuprolide acetate 4 (100) | PR 2 (50) SD 2 (50) | 8 (3–13+) 1 | NA | 11 | AWD 3 (75) DOD 1 (25) |
Assi, 2017 [39] | retrospective case report | 2013–2016 | 1 | I | S ×1, CT ×2 | letrozole 1 (100) | PR 1 (100) | 35 1 | 44+ 1 | 44 1 | AWD 1 (100) |
Hardy, 2005 [20] | retrospective case report | 1999–2004 | 1 | >II | S ×3, CT ×2 | megestrol/tamoxifen 1 (100) | CR 1 (100) | 60+ 1 | 60+ 1 | 60 1 | NED 1 (100) |
Abdul Munem, 2012 [40] | retrospective case report | 2009–2010 | 1 | NA | S ×3, CT ×3, RT ×1 | anastrozole 1 (100) | SD 1 (100) | 20+ | 20+ | 20 | AWD 1 (100) 1 |
AlHilli, 2012 [41] | retrospective case report | 2010 | 1 | IA | S ×7, CT ×1, RT ×4 | letrozole 1 (100) | PR 1 | 6 | NA | 6 | AWD 1 (100) 1 |
van Meurs, 2015 [42] | retrospective cohort | 1979–2013 | 16 2 | I-III | S 16 (100) CT 8 (50) RT 7 (44) AHT 6 (38) | anastrozole 2 (9) goserelin 2 (9) letrozole 6 (27) megestrol acetate 6 (27) tamoxifen 5 (23) aromatase inhibitor 1 (5) | SD 14 (64) PD 8 (36) | 4 (2–53) 1 | NA | NA | NED 1 (6) AWD 8 (50) DOD 5 (31) DOC 2 (13) |
Wilson, 2015 [30] | retrospective cohort | 1955–2012 | 26 3 | IA-IC | S 26 (100) CT ns, RT ns | AHT 126 (100) | CR 1 (2) PR 5 (11) SD 21 (48) PD 12 (27) 4 | 18 (6–54) | NA | NA | NA |
Lamm, 2016 [43] | retrospective case report | 2012 | 1 | IA 1 | S ×6, AHT ×1 | letrozole 1 (100) | CR 1 (100) | 8 | NA | 12 1 | AWD 1 (100) |
Schwartz, 2016 [44] | retrospective case report | 2008–2009 | 1 5 | IA | S ×2, CT ×1, RT ×1 | anastrozole 1 (100) | PR | 19 (8–30) | NA | 37.5 (30–45) | AWD 1 (100) |
Yazigi, 2016 [45] | retrospective case report | 2003–2014 | 1 | NA | S ×5, CT ×2, AHT ×2 | letrozole 1 (100) | PR 1 | 11 | 31 | 31 | DOD 1 (100) |
Tsubamoto, 2019 [46] | retrospective cohort | 2007–2015 | 3 | NA | S 3 (100) | leuprolide acetate 3 (100) | SD 3 (100) | 4 (4–22) | 27 (6–74) | 27 (6–74) | AWD 1 (33) DOD 2 (67) |
Moon, 2021 [47] | retrospective case report | NA | 1 | NA | S ×3, CT ×3, AHT ×2, RT ×1 | megestrol acetate/tamoxifen 1 (100) | SD1 | 22 | NA | 48 1 | AWD |
Banerjee, 2021 [33] | retrospective cohort | 2012–2017 | 41 GCT | NA | S 41 (100) CT 16 (39) RT 5 (13) ns 19 (46) | anastrozole 38 (100) | PR 1 (3) SD 29 (76) PD 8 (21) | 8.6 (95% CI 5.5–13.5) | NA | 52 | NA |
3.3. Quality Assessment
3.4. Chemotherapy
3.5. Anti-Hormonal Therapy
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Appendix A. Comprehensive Search Strategies
Appendix B. Risk of Bias Results per Type of Study
References
- Schumer, S.T.; Cannistra, S.A. Granulosa cell tumor of the ovary. J. Clin. Oncol. 2003, 21, 1180–1189. [Google Scholar] [CrossRef] [PubMed]
- Shah, S.P.; Köbel, M.; Senz, J.; Morin, R.D.; Clarke, B.A.; Wiegand, K.C.; Leung, G.; Zayed, A.; Mehl, E.; Kalloger, S.E. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 2009, 360, 2719–2729. [Google Scholar] [CrossRef] [PubMed]
- Young, R.H.; Dickersin, G.R.; Scully, R.E. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am. J. Surg. Pathol. 1984, 8, 575–596. [Google Scholar] [CrossRef] [PubMed]
- Mangili, G.; Ottolina, J.; Gadducci, A.; Giorda, G.; Breda, E.; Savarese, A.; Candiani, M.; Frigerio, L.; Scarfone, G.; Pignata, S.; et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br. J. Cancer 2013, 109, 29–34. [Google Scholar] [CrossRef]
- Berek, J.S.; Kehoe, S.T.; Kumar, L.; Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. 2018, 143, 59–78. [Google Scholar] [CrossRef]
- Ray-Coquard, I.; Morice, P.; Lorusso, D.; Prat, J.; Oaknin, A.; Pautier, P.; Colombo, N. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018, 29, iv1–iv18. [Google Scholar] [CrossRef]
- Tokunaga, H.; Mikami, M.; Nagase, S.; Kobayashi, Y.; Tabata, T.; Kaneuchi, M.; Satoh, T.; Hirashima, Y.; Matsumura, N.; Yokoyama, Y. The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J. Gynecol. Oncol. 2021, 32, e49. [Google Scholar] [CrossRef]
- Brown, J.; Shvartsman, H.S.; Deavers, M.T.; Ramondetta, L.M.; Burke, T.W.; Munsell, M.F.; Gershenson, D.M. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol. Oncol. 2005, 97, 489–496. [Google Scholar] [CrossRef]
- Gershenson, D.M.; Morris, M.; Burke, T.W.; Levenback, C.; Matthews, C.M.; Wharton, J.T. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet. Gynecol. 1996, 87, 527–531. [Google Scholar] [CrossRef]
- Ray-Coquard, I.; Brown, J.; Harter, P.; Provencher, D.M.; Fong, P.C.; Maenpaa, J.; Ledermann, J.A.; Emons, G.; Rigaud, D.B.; Glasspool, R.M. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int. J. Gynecol. Cancer 2014, 24, S42–S47. [Google Scholar] [CrossRef]
- Brown, J.; Shvartsman, H.S.; Deavers, M.T.; Burke, T.W.; Munsell, M.F.; Gershenson, D.M. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J. Clin. Oncol. 2004, 22, 3517–3523. [Google Scholar] [CrossRef] [PubMed]
- Homesley, H.D.; Bundy, B.N.; Hurteau, J.A.; Roth, L.M. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol. Oncol. 1999, 72, 131–137. [Google Scholar] [CrossRef]
- Pautier, P.; Gutierrez-Bonnaire, M.; Rey, A.; Sillet-Bach, I.; Chevreau, C.; Kerbrat, P.; Morice, P.; Duvillard, P.; Lhommé, C. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int. J. Gynecol. Cancer 2008, 18, 446–452. [Google Scholar] [CrossRef] [PubMed]
- Colombo, N.; Sessa, C.; Landoni, F.; Sartori, E.; Pecorelli, S.; Mangioni, C. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet. Gynecol. 1986, 67, 265–268. [Google Scholar] [CrossRef] [PubMed]
- Sigismondi, C.; Gadducci, A.; Lorusso, D.; Candiani, M.; Breda, E.; Raspagliesi, F.; Cormio, G.; Marinaccio, M.; Mangili, G. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. Gynecol. Oncol. 2012, 125, 673–676. [Google Scholar] [CrossRef] [PubMed]
- Van Meurs, H.S.; Buist, M.R.; Westermann, A.M.; Sonke, G.S.; Kenter, G.G.; van der Velden, J. Effectiveness of chemotherapy in measurable granulosa cell tumors: A retrospective study and review of literature. Int. J. Gynecol. Cancer 2014, 24, 496–505. [Google Scholar] [CrossRef]
- Jules-Elysee, K.; White, D.A. Bleomycin-induced pulmonary toxicity. Clin. Chest Med. 1990, 11, 1–20. [Google Scholar] [CrossRef]
- Boyd, L.R.; Muggia, F.M. Carboplatin/paclitaxel induction in ovarian cancer: The finer points. Oncology 2018, 32, 418–420, 422–424. [Google Scholar]
- Steegers, E.A.; Fauser, B.C.; Hilders, C.G.; Jaddoe, V.W.; Massuger, L.F.; Schoenmakers, S.; van der Post, J.A. Textbook of Obstetrics and Gynaecology: A Life Course Approach; Bohn Stafleu van Loghum: Houten, The Netherlands, 2019. [Google Scholar]
- Hardy, R.D.; Bell, J.G.; Nicely, C.J.; Reid, G.C. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: Case report and review of the literature. Gynecol. Oncol. 2005, 96, 865–869. [Google Scholar] [CrossRef]
- Farinola, M.A.; Gown, A.M.; Judson, K.; Ronnett, B.M.; Barry, T.S.; Movahedi-Lankarani, S.; Vang, R. Estrogen receptor α and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int. J. Gynecol. Pathol. 2007, 26, 375–382. [Google Scholar] [CrossRef]
- Van Meurs, H.S.; van Lonkhuijzen, L.R.; Limpens, J.; van der Velden, J.; Buist, M.R. Hormone therapy in ovarian granulosa cell tumors: A systematic review. Gynecol. Oncol. 2014, 134, 196–205. [Google Scholar] [CrossRef] [PubMed]
- Booth, A.; Clarke, M.; Dooley, G.; Ghersi, D.; Moher, D.; Petticrew, M.; Stewart, L. The nuts and bolts of PROSPERO: An international prospective register of systematic reviews. Syst. Rev. 2012, 1, 2. [Google Scholar] [CrossRef] [PubMed]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021, 88, 105906. [Google Scholar] [CrossRef] [PubMed]
- Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—a web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef] [PubMed]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar] [CrossRef] [PubMed]
- Sterne, J.A.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.-Y.; Corbett, M.S.; Eldridge, S.M. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366, l4898. [Google Scholar] [CrossRef] [PubMed]
- Wells, G.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. Newcastle-Ottawa Quality Assessment Scale Cohort Studies; University of Ottawa: Ottawa, ON, Canada, 2014. [Google Scholar]
- Murad, M.H.; Sultan, S.; Haffar, S.; Bazerbachi, F. Methodological quality and synthesis of case series and case reports. BMJ Evid. Based Med. 2018, 23, 60–63. [Google Scholar] [CrossRef]
- Wilson, M.K.; Fong, P.; Mesnage, S.; Chrystal, K.; Shelling, A.; Payne, K.; Mackay, H.; Wang, L.; Laframboise, S.; Rouzbahman, M.; et al. Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecol. Oncol. 2015, 138, 285–291. [Google Scholar] [CrossRef]
- Burton, E.R.; Brady, M.; Homesley, H.D.; Rose, P.G.; Nakamura, T.; Kesterson, J.P.; Rotmensch, J.; Tate Thigpen, J.; Van Le, L. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol. Oncol. 2020, 140, 48–52. [Google Scholar] [CrossRef]
- Ray-Coquard, I.; Harter, P.; Lorusso, D.; Dalban, C.; Vergote, I.; Fujiwara, K.; Gladieff, L.; Lück, H.J.; Floquet, A.; Chevalier-Place, A.; et al. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. JAMA Oncol. 2020, 6, 1923–1930. [Google Scholar] [CrossRef]
- Banerjee, S.N.; Tang, M.; O’Connell, R.L.; Sjoquist, K.; Clamp, A.R.; Millan, D.; Nottley, S.; Lord, R.; Mullassery, V.M.; Hall, M.; et al. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Gynecol. Oncol. 2021, 163, 72–78. [Google Scholar] [CrossRef] [PubMed]
- Tresukosol, D.; Kudelka, A.P.; Edwards, C.L.; Charnsangavej, C.; Narboni, N.; Kavanagh, J.J. Recurrent ovarian granulosa cell tumor: A case report of a dramatic response to Taxol. Int. J. Gynecol. Cancer 1995, 5, 156–159. [Google Scholar] [CrossRef] [PubMed]
- Shavit, T.; Bruchim, I.; Ben-Harim, Z.; Fishman, A. Successful response to docetaxel treatment in recurrent ovarian granulosa cell tumor: A case report. Eur. J. Gynaecol. Oncol. 2012, 33, 419–420. [Google Scholar] [PubMed]
- Uygun, K.; Aydiner, A.; Saip, P.; Kocak, Z.; Basaran, M.; Dincer, M.; Topuz, E. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol. Oncol. 2003, 88, 400–403. [Google Scholar] [CrossRef]
- Pectasides, D.; Papaxoinis, G.; Fountzilas, G.; Aravantinos, G.; Pectasides, E.; Mouratidou, D.; Economopoulos, T.; Andreadis, C. Adult granulosa cell tumors of the ovary: A clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer. Res. 2008, 28, 1421–1427. [Google Scholar]
- Fishman, A.; Kudelka, A.P.; Tresukosol, D.; Edwards, C.L.; Freedman, R.S.; Kaplan, A.L.; Girtanner, R.E.; Kavanagh, J.J. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J. Reprod Med. 1996, 41, 393–396. [Google Scholar]
- Assi, T.; Kourie, H.R.; El Rassy, E.; Moussa, T.; Kattan, J. Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole. Anticancer. Drugs 2017, 28, 931–933. [Google Scholar] [CrossRef]
- Abdul Munem, A.; Al-Bahrani, B.; Mehdi, I.; Kamona, A.; Nadas, A.M. Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: Overview and case report. J. Pak. Med. Assoc. 2012, 62, 505–507. [Google Scholar]
- Alhilli, M.M.; Long, H.J.; Podratz, K.C.; Bakkum-Gamez, J.N. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature. J. Obs. Gynaecol. Res. 2012, 38, 340–344. [Google Scholar] [CrossRef]
- Van Meurs, H.S.; van der Velden, J.; Buist, M.R.; van Driel, W.J.; Kenter, G.G.; van Lonkhuijzen, L.R. Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary. Acta Obstet. Gynecol. Scand. 2015, 94, 1269–1275. [Google Scholar] [CrossRef]
- Lamm, W.; Schiefer, A.; Nöbauer, I.M.; Horvat, R.; Speiser, P.; Köstler, W.J. Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary. J. Clin. Oncol. 2016, 34, e31–e33. [Google Scholar] [CrossRef] [PubMed]
- Schwartz, M.; Huang, G.S. Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor. Gynecol. Oncol. Rep. 2015, 15, 20–21. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Yazigi, R.; Rodríguez, T.; Buckel, E.; Wash, A. Ovarian granulosa cell tumour and letrozole: A case report. J. Obs. Gynaecol. 2016, 36, 122–123. [Google Scholar] [CrossRef] [PubMed]
- Tsubamoto, H.; Ueda, T.; Inoue, K.; Isono-Nakata, R.; Saeki, S.; Kato, Y.; Shibahara, H. Effects of leuprorelin for the treatment of recurrent gynecological cancer by assessment including self-administered quality-of-life questionnaire. J. Obstet. Gynaecol. Res. 2018, 45, 203–209. [Google Scholar] [CrossRef]
- Moon, A.S.; Dorigo, O. Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary. Gynecol. Oncol. Rep. 2021, 36, 100770. [Google Scholar] [CrossRef]
- McGuinness, L.A.; Higgins, J.P. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res. Synth. Methods 2021, 12, 55–61. [Google Scholar] [CrossRef]
- Schultz, K.A.; Harris, A.K.; Schneider, D.T.; Young, R.H.; Brown, J.; Gershenson, D.M.; Dehner, L.P.; Hill, D.A.; Messinger, Y.H.; Frazier, A.L. Ovarian Sex Cord-Stromal Tumors. J. Oncol Pr. 2016, 12, 940–946. [Google Scholar] [CrossRef]
- Al Harbi, R.; McNeish, I.A.; El-Bahrawy, M. Ovarian sex cord-stromal tumors: An update on clinical features, molecular changes, and management. Int. J. Gynecol. Cancer 2021, 31, 161–168. [Google Scholar] [CrossRef]
- Woodcock, J.; LaVange, L.M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 2017, 377, 62–70. [Google Scholar] [CrossRef]
- How, J.A.; Jazaeri, A.; Westin, S.N.; Sood, A.K.; Ramondetta, L.M.; Xu, M.; Abonofal, A.; Karp, D.D.; Subbiah, V.; Stephen, B. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: A case series from a phase II basket trial. Investig. New Drugs 2021, 39, 829–835. [Google Scholar] [CrossRef]
- Haltia, U.-M.; Andersson, N.; Yadav, B.; Färkkilä, A.; Kulesskiy, E.; Kankainen, M.; Tang, J.; Bützow, R.; Riska, A.; Leminen, A. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecol. Oncol. 2017, 144, 621–630. [Google Scholar] [CrossRef] [PubMed]
- Roze, J.; Sendino Garví, E.; Stelloo, E.; Stangl, C.; Sereno, F.; Duran, K.; Groeneweg, J.; Paijens, S.; Nijman, H.; van Meurs, H. In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors. Cancers 2021, 13, 368. [Google Scholar] [CrossRef] [PubMed]
Regimen | Number of Regimens | CR n (%) | PR n (%) | SD n (%) | PD n (%) | Unknown n (%) |
---|---|---|---|---|---|---|
Platinum-based | 37 | 4 (11) | 11 (30) | 10 (27) | 10 (27) | 2 (5) 1 |
Taxane-based | 9 | 0 (0) | 2 (22) | 3 (33) | 4 (45) | 0 (0) |
Platinum taxane combination | 6 | 2 (33) | 0 (0) | 2 (33) | 2 (33) | 0 (0) |
Other 2 | 6 | 0 (0) | 0 (0) | 1 (17) | 5 (83) | 0 (0) |
Total | 58 | 6 (10) | 13 (22) | 16 (28) | 21 (36) | 2 (4) |
Regimen | Number of Regimens | CR n (%) | PR n (%) | SD n (%) | PD n (%) | Unknown n (%) |
---|---|---|---|---|---|---|
Platinum-based | 37 | 4 (11) | 11 (30) | 10 (27) | 10 (27) | 2 (5) 1 |
Taxane-based | 7 | 0 (0) | 1 (14) | 2 (29) | 4 (57) | 0 (0) |
Platinum taxane combination | 6 | 2 (33) | 0 (0) | 2 (33) | 2 (33) | 0 (0) |
Other 2 | 6 | 0 (0) | 0 (0) | 1 (17) | 5 (83) | 0 (0) |
Total | 56 | 5 (9) | 12 (21) | 16 (28) | 22 (39) | 2 (3) |
Regimen | Number of Regimens | CR n (%) | PR n (%) | SD n (%) | PD n (%) | Unknown n (%) |
---|---|---|---|---|---|---|
Aromatase inhibitor | 16 | 1 (6) | 5 (31) | 7 (44) | 3 (19) | 0 (0) |
GnRH agonist | 9 | 0 (0) | 2 (22) | 6 (67) | 1 (11) | 0 (0) |
Progestin | 6 | 0 (0) | 0 (0) | 5 (83) | 1 (17) | 0 (0) |
SERM | 5 | 0 (0) | 0 (0) | 2 (40) | 3 (60) | 0 (0) |
Combinations | 2 | 1 (50) | 0 (0) | 1 (50) | 0 (0) | 0 (0) |
Type unknown | 44 | 1 (3) | 5 (11) | 21 (48) | 12 (27) | 5 (11) 1 |
Total | 82 | 3 (4) | 12 (15) | 42 (51) | 20 (24) | 5 (6) |
Regimen | Number of Regimens | CR n (%) | PR n (%) | SD n (%) | PD n (%) | Unknown n (%) |
---|---|---|---|---|---|---|
Aromatase inhibitor | 9 | 0 (0) | 0 (0) | 6 (67) | 3 (33) | 0 (0) |
GnRH agonist | 9 | 0 (0) | 2 (22) | 6 (67) | 1 (11) | 0 (0) |
Progestin | 6 | 0 (0) | 0 (0) | 5 (83) | 1 (17) | 0 (0) |
SERM | 5 | 0 (0) | 0 (0) | 2 (40) | 3 (60) | 0 (0) |
Type unknown | 44 | 1 (3) | 5 (11) | 21 (48) | 12 (27) | 5 (11) 1 |
Total | 73 | 1 (1) | 7 (10) | 40 (55) | 20 (27) | 5 (7) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brink, G.J.; Groeneweg, J.W.; Hooft, L.; Zweemer, R.P.; Witteveen, P.O. Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. Cancers 2022, 14, 2998. https://doi.org/10.3390/cancers14122998
Brink GJ, Groeneweg JW, Hooft L, Zweemer RP, Witteveen PO. Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. Cancers. 2022; 14(12):2998. https://doi.org/10.3390/cancers14122998
Chicago/Turabian StyleBrink, Geertruid J., Jolijn W. Groeneweg, Lotty Hooft, Ronald P. Zweemer, and Petronella O. Witteveen. 2022. "Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review" Cancers 14, no. 12: 2998. https://doi.org/10.3390/cancers14122998
APA StyleBrink, G. J., Groeneweg, J. W., Hooft, L., Zweemer, R. P., & Witteveen, P. O. (2022). Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. Cancers, 14(12), 2998. https://doi.org/10.3390/cancers14122998